Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zhengye Biotechnology Holding Limited Ordinary Shares stock (ZYBT) is currently trading at $0.88. Zhengye Biotechnology Holding Limited Ordinary Shares PS ratio (Price-to-Sales) is 0.27. WallStSmart rates ZYBT as Sell.
- ZYBT PE ratio analysis and historical PE chart
- ZYBT PS ratio (Price-to-Sales) history and trend
- ZYBT intrinsic value — DCF, Graham Number, EPV models
- ZYBT stock price prediction 2025 2026 2027 2028 2029 2030
- ZYBT fair value vs current price
- ZYBT insider transactions and insider buying
- Is ZYBT undervalued or overvalued?
- Zhengye Biotechnology Holding Limited Ordinary Shares financial analysis — revenue, earnings, cash flow
- ZYBT Piotroski F-Score and Altman Z-Score
- ZYBT analyst price target and Smart Rating
Zhengye Biotechnology Holding
📊 No data available
Try selecting a different time range
Smart Analysis
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Key Strengths (2)
Paying less than $1 for every $1 of annual revenue
Trading at 1.06x book value, attractively priced
Supporting Valuation Data
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Revenue declining -34.40%, a shrinking business
Earnings declining -79.60%, profits shrinking
Company is losing money with a negative profit margin
Very low institutional interest at 0.49%
Micro-cap company with very limited liquidity and high volatility
Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 9.0/10) while 7 fall into concern territory (avg 0.7/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Sales, Price/Book. Valuation metrics including Price/Sales (0.27), Price/Book (1.06) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Growth concerns include Revenue Growth at -34.40%, EPS Growth at -79.60%, which may limit upside. Profitability pressure is visible in Return on Equity at -6.38%, Operating Margin at -46.30%, Profit Margin at -12.60%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -6.38% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -34.40% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZYBT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZYBT's Price-to-Sales ratio of 0.27x trades at a deep discount to its historical average of 0.86x (38th percentile). The current valuation is 90% below its historical high of 2.65x set in Apr 2025, and 28% above its historical low of 0.21x in Feb 2026. Over the past 12 months, the PS ratio has compressed from ~1.3x as trailing revenue scaled faster than the stock price.
Compare ZYBT with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Zhengye Biotechnology Holding Limited Ordinary Shares (ZYBT) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
Zhengye Biotechnology Holding Limited Ordinary Shares is in a turnaround phase, with management focused on restoring profitability. Revenue reached 154M with 34% decline year-over-year. The company is currently unprofitable, posting a -12.6% profit margin.
Key Findings
Generating 13M in free cash flow and 41M in operating cash flow. Earnings are translating into actual cash generation.
Revenue contracted 34% YoY. Worth determining whether this is cyclical or structural.
The company is unprofitable with a -12.6% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact Zhengye Biotechnology Holding Limited Ordinary Shares.
Bottom Line
Zhengye Biotechnology Holding Limited Ordinary Shares is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Zhengye Biotechnology Holding Limited Ordinary Shares(ZYBT)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
Zhengye Biotechnology Holding Limited (Ticker: ZYBT) is an innovative biotechnology firm focused on the development and commercialization of advanced biopharmaceutical products. The company leverages its proprietary technologies and a diverse product pipeline to address critical medical needs, positioning itself strategically to enhance treatment outcomes across multiple therapeutic areas. With a robust commitment to research and development, ZYBT aims to drive significant growth and deliver substantial value to its investors, while maintaining a strong emphasis on quality and innovation within the dynamic biotechnology landscape.